Effects of Budesonide & Budesonide/Formoterol on Smoking Asthmatic Subjects
Information source: Laval University
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Intervention: budesonide and budesonide/formoterol (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Laval University
Summary
A reduced response to inhaled corticosteroids (ICS) has been reported in smoking compared to
non-smoking asthmatic patients. However, the comparative response to other currently
prescribed medications such as combination therapy of long-acting beta agonists and ICS
remain to be further evaluated.
No significant differences were found between our group of subjects in regard to changes in
asthma control pulmonary function and airway inflammation following budesonide or the
association of budesonide with formoterol for a period of 2 months. This should be further
explored in larger groups of subjects.
Clinical Details
Official title: Comparative Effects of Budesonide and Budesonide/Formoterol (Symbicort) on Asthma Control in Smoking Asthmatic Subjects: A Pilot Study
Study design: N/A
Eligibility
Minimum age: 18 Years.
Maximum age: 45 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Asthmatic non-smokers or ex-smokers (less than 10 pack/years)
- Asthmatic smokers (more than 5 cigarettes a day and more than 5 pack/years
- FEV1 greater than 70%
- No more than 3 doses of rescue medication (bronchodilator) per day
Exclusion Criteria:
- Mentally or legally incapacitated thus preventing informed consent from being
obtained
- Other pulmonary disorder
- History of upper respiratory tract infection in the last month
- Pregnant or lactating women
Locations and Contacts
Laval Hospital, Quebec G1V 4G5, Canada
Hôpital du Sacré-Coeur de Montreal, Montréal, Quebec H4J 1C5, Canada
Additional Information
Last updated: June 5, 2008
|
